The company maintains a conservative debt-to-equity ratio of 0.16, though total assets have eroded to $178.1M as of 2026Q1 due to persistent net losses.
| Total Current Assets | 166.68M | 186.72M | 217.27M | 51.96M | 79.8M |
| Cash & Short-Term Investments | 141.18M | 159.26M | 194.37M | 34.49M | 68.23M |
| Cash Only | 45.25M | 40.48M | 194.37M | 34.49M | 68.23M |
| Short-Term Investments | 95.93M | 118.78M | 0 | 0 | 0 |
| Accounts Receivable | 15.71M | 15.05M | 10.88M | 7.96M | 5.29M |
| Days Sales Outstanding | 53.09 | 61.69 | 60.67 | 64.2 | 74.56 |
| Inventory | 6.9M | 7.29M | 6.94M | 5.87M | 4.08M |
| Days Inventory Outstanding | 204.85 | 246.56 | 291.24 | 303.29 | 335.75 |
| Other Current Assets | 2.88M | 5.12M | 5.09M | 3.65M | 2.19M |
| Total Non-Current Assets | 11.4M | 9.09M | 8.14M | 6.96M | 6.66M |
| Property, Plant & Equipment | 3.97M | 4.33M | 4.45M | 3.74M | 3.87M |
| Fixed Asset Turnover | 24.52x | 20.59x | 14.72x | 12.10x | 6.69x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 958K | 805K | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 6.47M | 3.95M | 3.69M | 3.22M | 2.79M |
| Total Assets | 178.08M | 195.8M | 225.41M | 58.92M | 86.46M |
| Asset Turnover | 0.49x | 0.45x | 0.29x | 0.77x | 0.30x |
| Asset Growth % | 584.84% | -13.14% | 282.56% | -31.85% | - |
| Total Current Liabilities | 16.18M | 19.19M | 12.99M | 21.6M | 9.86M |
| Accounts Payable | 1.98M | 2.84M | 1.14M | 732K | 423K |
| Days Payables Outstanding | 73.78 | 96.01 | 47.99 | 37.83 | 34.85 |
| Short-Term Debt | 1.14M | 0 | 0 | 11.83M | 2.5M |
| Deferred Revenue (Current) | 440K | 0 | 97K | 206K | 343K |
| Other Current Liabilities | 7.22M | 15.25M | 5M | 3.73M | 2.51M |
| Current Ratio | 10.30x | 9.73x | 16.73x | 2.41x | 8.09x |
| Quick Ratio | 9.87x | 9.35x | 16.19x | 2.13x | 7.68x |
| Cash Conversion Cycle | 184.16 | 212.24 | 303.92 | 329.66 | 375.46 |
| Total Non-Current Liabilities | 21.08M | 21.17M | 21.26M | 149.57M | 162.99M |
| Long-Term Debt | 19.92M | 19.81M | 19.56M | 0 | 12.72M |
| Capital Lease Obligations | 3.57M | 1.36M | 1.31M | 1.68M | 2.37M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 106K | 106K | 356K | 147.85M | 147.9M |
| Total Liabilities | 37.27M | 40.47M | 34.25M | 171.17M | 172.86M |
| Total Debt | 22.12M | 22.28M | 21.96M | 14.2M | 18.22M |
| Net Debt | -23.14M | -18.2M | -172.41M | -20.29M | -50.02M |
| Debt / Equity | 0.16x | 0.14x | 0.11x | - | - |
| Debt / EBITDA | -0.35x | - | - | - | - |
| Net Debt / EBITDA | 0.37x | - | - | - | - |
| Interest Coverage | -60.87x | -27.26x | -19.31x | -13.04x | -22.18x |
| Total Equity | 140.81M | 155.34M | 191.16M | -112.25M | -86.4M |
| Equity Growth % | 415.03% | -18.74% | 270.3% | -29.92% | - |
| Book Value per Share | 3.74 | 4.25 | 16.00 | -4.81 | -3.70 |
| Total Shareholders' Equity | 140.81M | 155.34M | 191.16M | -112.25M | -86.4M |
| Common Stock | 38K | 38K | 36K | 5K | 5K |
| Retained Earnings | -240.09M | -220.36M | -166.94M | -126.49M | -97.03M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 18K | 159K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Liquidity and Burn Rate
As reported in recent financial statements, CeriBell's total assets have declined from a peak of $225.4M in 2024Q4 to $178.1M in 2026Q1, reflecting a consistent trend of capital consumption as the company funds its aggressive market penetration strategy within the acute care hospital sector.
The contraction in total assets suggests that the company is rapidly deploying its cash reserves to support commercial infrastructure rather than building a long-term asset base. Investors should monitor whether this trajectory indicates a structural reliance on external financing to sustain operations as the company attempts to reach a break-even scale.
Based on the company's 2026Q1 filings, cash reserves have fluctuated significantly, dropping to $45.3M from a high of $194.4M in 2024Q4, which indicates a tightening liquidity buffer relative to the ongoing operational burn required to maintain the current sales force and clinical support infrastructure.
While the current ratio of 10.30 appears superficially strong, it is heavily influenced by the composition of current assets and does not account for the high cash burn rate observed in recent quarters. The rapid depletion of cash suggests that the company may face significant liquidity pressure if it fails to achieve operating leverage in the near term.
According to the latest balance sheet data, CeriBell maintains a debt-to-equity ratio of 0.16 as of 2026Q1, with total debt standing at $22.1M, suggesting that management has utilized modest leverage to supplement its capital structure while navigating a period of persistent negative net earnings.
The relatively low leverage ratio may provide some flexibility, but the company's inability to generate positive cash flow makes even this modest debt load a potential risk factor. Investors should consider whether the current debt service requirements could become burdensome if the company's revenue growth trajectory encounters unexpected headwinds.
As indicated by the company's reported figures, retained earnings have deteriorated to -$240.1M in 2026Q1, a clear reflection of the sustained losses incurred during the company's transition from a research-focused entity to a commercial-stage medical device provider with significant ongoing operating expenses.
The persistent growth in accumulated deficits highlights the high cost of customer acquisition and the challenge of scaling a specialized diagnostic platform. This trend warrants further investigation into the company's long-term path to profitability and the potential for future equity dilution to bridge the funding gap.
Quick answers to the most common questions about buying CBLL stock.
As of 2025, CeriBell, Inc. (CBLL) had total assets of $195.8M including $186.7M in current assets.
CeriBell, Inc. (CBLL) carries total debt of $22.3M, offset by $159.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
CeriBell, Inc. (CBLL) has total shareholders' equity (book value) of $155.3M ($4.25 book value per share). Book value represents the net worth of the company belonging to common stock holders.
CeriBell, Inc. (CBLL) reported a current ratio of 9.73x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.